# 5-Amino-1MQ dosage guide

> Review 5-Amino-1MQ dosage information by administration route, with source-linked dose and schedule details.

Canonical: https://pepflow.app/peptides/5-amino-1mq/dosage/

Review oral 5-Amino-1MQ amounts, daily timing and course lengths for the NNMT-inhibiting compound. Calculate volume and syringe units using your own vial inputs.

[Full 5-Amino-1MQ library reference](<https://pepflow.app/peptides/5-amino-1mq/>)

## 5-Amino-1MQ dosage chart

This summary table compares available dose amounts and schedules by administration route.

| Route | Dose | Frequency & duration |
| --- | --- | --- |
| Oral | 50–100 mg | Daily · 8–12 wk |

## 5-Amino-1MQ dosage by administration route

### 5-Amino-1MQ oral dosage

Reported-use amounts for 5-Amino-1MQ are 50–100 mg per administration, daily, for 8–12 wk.[\[10\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-10>)

5-Amino-1MQ inhibits nicotinamide N-methyltransferase and affects methylation and NAD-related metabolism. It is a small molecule rather than a peptide; a human fat-loss benefit has not been established.[\[1\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-1>) [\[2\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-2>) [\[3\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-3>) [\[4\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-4>) [\[10\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-10>)

### Frequency and timing

Morning is the listed timing for the oral pattern.[\[5\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-5>) [\[10\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-10>)

### Cycle length and breaks

Oral: 8–12 wk. A standard break interval between courses is not established.[\[10\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-10>)

## 5-Amino-1MQ dosage calculator

Convert your chosen 5-Amino-1MQ amount into volume and U-100 syringe units. Adjust the inputs to match your vial and preparation.

For preparation terms and concentration basics, see the [reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>). Follow the arithmetic in the [concentration calculation walkthrough](<https://pepflow.app/blog/how-to-calculate-final-concentration/>).

## 5-Amino-1MQ safety and side effects

### Approval and product quality

5-Amino-1MQ is not an FDA-approved drug.[\[2\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-2>) [\[9\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-9>)

### Side effects and long-term safety

Human pharmacokinetics, active dose, accumulation, washout, dose-response and long-term exposure are not characterized. Product identity, gastrointestinal or neurologic tolerability, liver metabolism, methylation and cancer-related biology are key considerations for oral products.[\[4\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-4>) [\[5\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-5>)

### Route-specific dosing limits

Mechanism-driven cautions matter most because there is no labeled clinical safety program. The external protocol gives a 50–150 mg daily range over 4–8 weeks but groups oral and subcutaneous administration together. It does not resolve a dependable route-specific injectable amount; the oral range must not be used as an injection instruction. Reported-use oral schedules and additional protocol patterns are not established human treatment regimens or approved product instructions.[\[5\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-5>) [\[4\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-4>) [\[10\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-10>)

## Stacks that include 5-Amino-1MQ

Open a stack dosage guide for its component amounts, schedules and supporting information.

[**NAD+ / MOTS-c / 5-Amino-1MQ** NAD+ / MOTS-c / 5-Amino-1MQ is a mitochondrial and metabolic stack concept built around cellular energy handling. Direct NAD+ provides the redox cofactor itself, MOTS-c targets mitochondrial stress-response signaling, and 5-Amino-1MQ targets NNMT-linked nicotinamide metabolism. NAD+ MOTS-c 5-Amino-1MQ](<https://pepflow.app/stacks/nad-mots-c-5-amino-1mq/dosage/>)

For a blend calculation, each component's amount and the final volume must be known. A total blend weight alone cannot tell you the dose of each component.

## Common 5-Amino-1MQ dosage questions

### Is there a standard human dose of 5-Amino-1MQ?

A transferable human dose for 5-Amino-1MQ has not been established. A product strength or reminder amount does not establish a treatment regimen.[\[10\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-10>)

### What dosage is listed for 5-Amino-1MQ?

Reported-use amounts for 5-Amino-1MQ are 50–100 mg per administration, daily, for 8–12 wk.[\[10\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-10>)

### Does 5-Amino-1MQ have a standard cycle or break interval?

Oral: 8–12 wk. A standard break interval between courses is not established.[\[10\]](<https://pepflow.app/peptides/5-amino-1mq/dosage/#source-10>)

## Sources

- [\[1\] **Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.** Biochemical pharmacology, 2018 Jan. animal.](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)
- [\[2\] **Search Drugs@FDA for 5-Amino-1MQ** U.S. Food and Drug Administration / openFDA. database query.](<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>)
- [\[3\] **Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.** Nature, 2014 Apr 10. review.](<https://pubmed.ncbi.nlm.nih.gov/24717514/>)
- [\[4\] **Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation.** Trends in pharmacological sciences, 2026 Jun. review.](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)
- [\[5\] **Exploring NNMT: from metabolic pathways to therapeutic targets.** Archives of pharmacal research, 2024 Dec. review.](<https://pubmed.ncbi.nlm.nih.gov/39604638/>)
- [\[6\] **A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD** Frontiers in Aging Neuroscience, 2019-09-12. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/31572171/>)
- [\[7\] **The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.** Cell metabolism, 2015 Mar 3. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/25738459/>)
- [\[8\] **The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.** Cell metabolism, 2018 Sep 4. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/29983246/>)
- [\[9\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[10\] **PepFlow peptide cheat sheet — reported-use and product-orientation reference (not clinical research)** PepFlow. reference catalog.](<https://pepflow.app/peptide-cheat-sheet/>)

[Full 5-Amino-1MQ library reference →](<https://pepflow.app/peptides/5-amino-1mq/>)

## Related

- [5-Amino-1MQ Peptide](<https://pepflow.app/peptides/5-amino-1mq/>)
- [Peptide reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>)
- [How to Calculate Final Concentration: A Practical Guide](<https://pepflow.app/blog/how-to-calculate-final-concentration/>)
- [NAD+ / MOTS-c / 5-Amino-1MQ dosage guide](<https://pepflow.app/stacks/nad-mots-c-5-amino-1mq/dosage/>)
